Radionuclide therapy practice and facilities in Europe

Hoefnagel, Cornelis A.; Clarke, Simon; Fischer, M.; Chatal, Jean‐François; Lewington, Val; Nilsson, Sanna; Troncone, L; Vieira, M. Rosário

doi:10.1007/s002590050389

Cited by 26 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The long-term implications of this to the patient are not yet known, although there is the potential for a reduction in the risk of secondary malignancies. The faster clearance of radioiodine from the body may also allow a quicker discharge from the radio-protective ward in hospitals, where the time of discharge is primarily dictated by radiation emission (16,17). Other authors have noted a reduction of a day or two in the hospital stay as an advantage of using exogenous rhTSH in clinical practice (18).…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective

Mernagh¹,

Campbell²,

Dietlein³

et al. 2006

eur j endocrinol

View full text Add to dashboard Cite

Objective: This investigation evaluated the cost-effectiveness of radioiodine remnant ablation following preparation with recombinant human TSH (rhTSH), compared with the standard preparation, whereby patients are rendered hypothyroid. Design: The economic evaluation relates to patients with well differentiated thyroid cancer who have undergone thyroidectomy, but have no metastases. The evaluation takes a societal perspective, considering costs and benefits to all parties. The benefits were expressed in units of quality-adjusted life years (QALY), so differences in life expectancy were captured with consideration of quality of life. Methods: A lifetime Markov model with Monte Carlo simulation of 100 000 patients was used to assess cost per QALY gained. The clinical inputs were sourced from a multi-centre, randomised controlled trial comparing remnant ablation success after rhTSH-preparation with hypothyroid preparation. The model applied German unit costs, however, the structure is generalisable to other jurisdictions. The additional cost of rhTSH procurement and administration is considered relative to the clinical benefits and cost offsets. These included avoidance of hypothyroidism, increased work productivity, earlier discharge from radioprotection and a theoretical reduction in the risk of secondary malignancy. The latter two benefits relate to faster radioiodine clearance after rhTSH preparation. Results: The additional benefits of rhTSH (0.0495 QALY) are obtained with an incremental societal cost of V47, equating to an incremental cost per QALY of V958. Sensitivity analyses had only a modest impact upon cost-effectiveness, with all one-way sensitivity results remaining under V15 000/QALY. Conclusions: The use of rhTSH prior to radioiodine ablation represents good value-for-money with the benefits to patient and society obtained at modest net cost. 155 405-414 European Journal of Endocrinology

show abstract

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective

Mernagh¹,

Campbell²,

Dietlein³

et al. 2006

eur j endocrinol

View full text Add to dashboard Cite

show abstract

“…Fundamentally, RSO is indicated for the local treatment of almost all kinds of chronic synovitis independent of the underlying disease (Mödder 1995a, b;Kampen et al 2001Kampen et al , 2002Kampen et al , 2007Fischer and Mödder 2002;Hoefnagel et al 1999;Farahati et al 2006;Brenner 2006, Das et al 2004Mödder and Mödder-Reese 2011).…”

Section: Indications/relevant Diseasesmentioning

confidence: 98%

Radionuclide Therapy of Inflammatory Joint Diseases (Radiation Synovectomy, Radiosynoviorthesis)

Mödder¹

2013

Therapeutic Nuclear Medicine

View full text Add to dashboard Cite

“…Future prospects The integration of 131 I-MIBG therapy with chemotherapy can be attempted to avoid the emergence of resistant clones which do not take up MIBG (24,37,107). However, in a recent prospective trial combining MIBG with chemotherapy, while an additive anti-tumour effect was demonstrated, pretreatment with MIBG increased toxicity which curtailed the proposed chemotherapy protocol (30).…”

Section: I-mibg Therapy For Malignant Chromaffin-cell Tumoursmentioning

confidence: 99%

Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours

Kaltsas

Rockall²,

Papadogias³

et al. 2004

Eur J Endocrinol

186

View full text Add to dashboard Cite

show abstract

Radionuclide therapy practice and facilities in Europe

Cited by 26 publications

References 0 publications

Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective

Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective

Radionuclide Therapy of Inflammatory Joint Diseases (Radiation Synovectomy, Radiosynoviorthesis)

Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours

Contact Info

Product

Resources

About